
Loading, please wait...

Loading, please wait...

Q1: What is the ownership structure of the new Jio-Allianz venture?
The venture is a 50:50 partnership between Jio Financial Services (JFSL) and the Germany-based Allianz Group.
Q2: When will the insurance operations officially begin?
Operations will start once the companies secure all necessary regulatory approvals from the relevant Indian authorities.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Jio Financial and Allianz sign a 50:50 joint venture for general and health insurance, targeting a ₹3.34 lakh crore market to boost India’s insurance covera...
5 months ago

A retrospective cohort study of 7,716 ICU patients from the MIMIC-IV database demonstrates that Gradient Boosting Decision Trees significantly outperform traditional SOFA scores in predicting in-hospital mortality among patients with sepsis and diabetes, with SHAP analysis providing clinical interpretability.
Today

Occult maternal malignancy accounts for 3.82% of persistent unreportable NIPT results with genomic noise. Multiple chromosomal aberrations, notably on chromosome 18, warrant thorough oncological evaluation and whole-body MRI to ensure timely maternal diagnosis while preserving fetal care.
Today

This article reviews the forensic and clinical complexities of acute myocarditis arising on left ventricular hypertrophy in children, highlighting early diagnostic red flags and multidisciplinary postmortem autopsy protocols.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday